Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Diurisa is a fixed-dose combination pharmaceutical drug containing furosemide (40 mg) and amiloride (10 mg). Furosemide is a loop diuretic that works by inhibiting the Na+/K+/2Cl- cotransporter in the thick ascending limb of the loop of Henle, leading to increased excretion of water, sodium, chloride, and potassium. Amiloride is a potassium-sparing diuretic that acts by blocking epithelial sodium channels (ENaC) in the distal tubule and collecting ducts, which reduces sodium reabsorption and helps to conserve potassium. This combination is used to treat edema (fluid retention) associated with conditions such as congestive heart failure, liver disease, and nephrotic syndrome, and also for hypertension. The amiloride component helps to mitigate the potassium loss often caused by furosemide alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Diurisa.